Serum tumor markers in skeletal metastasis

Japanese Journal of Clinical Oncology

Volumn 36, Issue 7, 2006, Pages 439-444

  Tsukushi, Satoshi ^a,d   Katagiri, Hirohisa ^b   Kataoka, Takae ^c   Nishida, Yoshihiro ^a   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c Nagoya Memorial Hospital   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Carbohydrate antigen 19 9; Carcinoembryonic antigen; Diagnosis; Skeletal metastasis; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; BONE METASTASIS; CANCER LOCALIZATION; CANCER SCREENING; CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; REVIEW; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33748118297     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl046     Document Type: Review

References (33)

1. Didolkar MS, Fanous N, Elias EG, Moore RH. Metastatic carcinomas from occult primary tumors: A study of 254 patients. Ann Surg 1977;186:625-30.
2. Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970;26:816-20.
3. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG. Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972;30:1469-72.
4. Simon MA, Karluk MB. Diagnostic strategy for orthopedic surgeons. Skeletal metastases of unknown origin. Clin Orthop 1982;166:96-103.
5. Stewart JF, Tattersall MH, Woods RL, Fox RM. Unknown primary adenocarcinoma: Incidence of over investigation and natural history. Br Med J 1979;1:1530-3.
6. Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: A retrospective study. Cancer 1999;86:533-537.
7. Chu TM, Nemoto TE. Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst 1973;51:1119-22.
8. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-81.
9. Gold P, Freedman SO. Demonstration of tumor specific antigen in human colonic carcinomata by immunological tolerance and absorption technique. J Exp Med 1964;121:439-62.
10. Goslin RH, Skarin AT, Zamcheck N, Carcinoembryonic antigen: A useful monitor of therapy of small cell lung cancer. JAMA 1981;246:2173-6.
11. Hayakawa T, Kondo T, Shibata T, Hamano H, Kitagawa M, Sakai Y, et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988;61:1827-31.
12. Vincent RG, Chu TM, Fergen TB, Ostrander M. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 1975;36:2069-76.
13. Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M. Carbohydrate antigen determinant and other tumor markers in gastrointestinal malignancies. Digestion 1985;31:67-76.
14. Bauer HCF, Wedin R. Survival after surgery for spinal and extremity metastases. Acta Orthop Scand 1995;66:143-146.
15. DeWald RL, Bridwell KH, Prodromas C, Rodts M. Reconstructive spinal surgery as palliation for metastatic malignancies of the spine. Spine 19851;10:21-6.
16. Fidler MW. Anterior decompression and stabilization of metastatic spinal fractures. J Bone Joint Surg 1986;68B:83-90.
17. Harrington KD. Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy. Clin Orthop 1988;223:177-97.
18. Hosono N, Yonenobu K, Fuji T, Ebara S, Yamashita K, Ono K. Vertebral body replacement with a ceramic prosthesis for metastatic spinal tumors. Spine 1995;20:2454-62.
19. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res 2001;7:2357-62.
20. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001;32:41-4.
21. Janssen CW Jr, Orjasaeter H. Carcinoembryonic antigen in patients with gastric carcinoma. Eur J Surg Oncol 1986;12:19-23.
22. Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2002;4:174-9.
23. Concannon JP, Dalbow MH, Frich JC Jr. Carcinoembryonic antigen (CEA) plasma levels in untreated cancer patients and patients with metastatic disease. Radiology 1973;108:191-193.
24. Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin JP, Pitkanen R, et al. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer 1984;49:135-9.
25. Martin EW Jr, Kibbey WE, DiVecchia L, Anderson G, Catalano P, Minton JP. Carcinoembryonic antigen: Clinical and historical aspects. Cancer 1976;37:62-81.
26. Vincent RG, Chu TM, Lane WW. Related articles. The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 1979;44:685-91.
27. Waalkes TP, Gehrke CW, Tormey DC, Woo KB, Kuo KC, Synder J, et al. Biologic markers in breast carcinoma. IV. Serum fucose-protein ratio: Comparisons with carcinoembryonic antigen and human chorionic gonadotrophin. Cancer 41:1871-1882.
28. Shinozaki T, Chigira M, Kato K. Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases. Cancer 1992;69:108-12.
29. Chen DS, Sung JL. Serum alphafetoprotein in hepatocellular carcinoma. Cancer 1977;40:779-83.
30. Delgado-Bolton RC, Frenandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003;44:1301-14.
31. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
32. Harrington KD. Orthopaedic Management of Metastatic Bone Disease. St Louis: The CV Mosby Company 1988;15-31.
33. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003;23:4095-9.